Thermo Fisher Scientific Cash Flow Statement
NYSE: TMOIndustrialsIndustrial Machinery/ComponentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Thermo Fisher Scientific free cash flow
In fiscal 2025, Thermo Fisher Scientific generated $7.82 billion of operating cash flow and spent $1.52 billion on capital expenditures. That left free cash flow of $6.29 billion, a free-cash-flow margin of 14.1% of revenue. Free cash flow was down 13.4% from the prior year's $7.27 billion.
Thermo Fisher Scientific returned $3.64 billion to shareholders: $636.0 million in dividends and $3.00 billion in share repurchases, equal to 58% of free cash flow. Free cash flow covered dividend payments 9.9 times.
Summary generated from market data by MetaCap's automated system. Methodology
Thermo Fisher Scientific cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 6.72B | 6.34B | 5.96B | 6.96B | 7.73B | 6.38B | 3.70B | 2.94B | 2.23B | 2.02B |
| Net Income growth (YoY) | +6.04% | +6.43% | -14.44% | -9.94% | +21.19% | +72.44% | +25.87% | +32.04% | +10.04% | +2.38% |
| Depreciation & Amortization | 1.05B | 1.16B | 1.07B | 986.00M | 831.00M | 658.00M | 564.00M | 2.27B | 2.03B | 1.76B |
| Stock-Based Compensation | 310.00M | 301.00M | 278.00M | 307.00M | 230.00M | 196.00M | 181.00M | 181.00M | 159.00M | 133.00M |
| Change in Working Capital | -79.00M | 14.00M | 55.00M | -607.00M | -790.00M | -1.75B | -615.00M | -477.00M | 694.00M | -135.00M |
| Operating Cash Flow | 7.82B | 8.67B | 8.41B | 9.15B | 9.31B | 8.29B | 4.97B | 4.54B | 4.00B | 3.26B |
| Capital Expenditures | -1.52B | -1.40B | -1.48B | -2.24B | -2.52B | -1.47B | -926.00M | -758.00M | -508.00M | -444.00M |
| Investing Cash Flow | -4.05B | -5.84B | -5.14B | -2.16B | -21.93B | -1.51B | -1.49B | -1.25B | -7.73B | -5.52B |
| Dividends Paid | -636.00M | -583.00M | -523.00M | -455.00M | -395.00M | -337.00M | -297.00M | -266.00M | -237.00M | -238.00M |
| Share Repurchases | -3.00B | -4.00B | -3.00B | -3.00B | -2.00B | -1.50B | -1.50B | -500.00M | -750.00M | -1.25B |
| Debt Issued | 7.76B | 1.20B | 5.94B | 3.19B | 18.14B | 3.46B | 5.64B | 690.00M | 6.46B | 7.60B |
| Debt Repaid | -2.41B | -3.61B | -5.78B | -375.00M | -11.74B | -710.00M | -6.36B | -2.05B | -3.30B | -4.33B |
| Financing Cash Flow | 1.80B | -6.79B | -3.62B | -2.81B | 6.58B | 959.00M | -3.12B | -2.24B | 3.85B | 2.76B |
| Net Change in Cash | 5.84B | -4.06B | -440.00M | 4.05B | -5.84B | 7.91B | 305.00M | 756.00M | 550.00M | 345.00M |
| Free Cash Flow | 6.29B | 7.27B | 6.93B | 6.91B | 6.79B | 6.82B | 4.05B | 3.79B | 3.50B | 2.81B |
This table shows 10 annual periods of Thermo Fisher Scientific's cash flow statement, from FY 2025 back to FY 2016, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TMO's reporting calendar. What is a cash flow statement?